[go: up one dir, main page]

CA3238583A1 - Formulations injectables et inhalables - Google Patents

Formulations injectables et inhalables Download PDF

Info

Publication number
CA3238583A1
CA3238583A1 CA3238583A CA3238583A CA3238583A1 CA 3238583 A1 CA3238583 A1 CA 3238583A1 CA 3238583 A CA3238583 A CA 3238583A CA 3238583 A CA3238583 A CA 3238583A CA 3238583 A1 CA3238583 A1 CA 3238583A1
Authority
CA
Canada
Prior art keywords
formulation
dimethyltryptamine
compound
salt
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3238583A
Other languages
English (en)
Inventor
Peter RANDS
Carol Routledge
Marie LAYZELL
Ellen James
Zelah JOEL
Tiffanie BENWAY
Meghan Good
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cybin UK Ltd
Original Assignee
Cybin UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TW110143066A external-priority patent/TWI891942B/zh
Priority claimed from GBGB2119021.0A external-priority patent/GB202119021D0/en
Application filed by Cybin UK Ltd filed Critical Cybin UK Ltd
Publication of CA3238583A1 publication Critical patent/CA3238583A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des formulations pharmaceutiques aqueuses, leurs procédés de production et leurs utilisations. Les formulations pharmaceutiques aqueuses comprennent un sel d'un composé de diméthyltryptamine facultativement substitué et de l'eau, avec un pH de 5 à 6,5, de préférence d'environ 5 à environ 6, et une concentration du composé de diméthyltryptamine facultativement substitué d'environ 10 mg/ml ou plus comme équivalent de base libre. Ces formulations peuvent comprendre une dose efficace d'un composé de diméthyltryptamine facultativement substitué destiné à être utilisé dans une thérapie assistée par médicaments psychédéliques dans un volume de 5 ml ou moins. De telles formulations sont appropriées de manière inattendue à la fois pour une injection intramusculaire et une inhalation nébulisée, étant à la fois stables et cliniquement acceptables, et présentent des utilisations potentielles dans le traitement de troubles psychiatriques ou neurologiques.
CA3238583A 2021-11-18 2022-11-18 Formulations injectables et inhalables Pending CA3238583A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
TW110143066A TWI891942B (zh) 2020-12-01 2021-11-18 氘化化合物
PCT/EP2021/082227 WO2022117359A1 (fr) 2020-12-01 2021-11-18 Composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés
TW110143066 2021-11-18
EPPCT/EP2021/082227 2021-11-18
GBGB2119021.0A GB202119021D0 (en) 2021-11-18 2021-12-24 Injectable and inhalable formulations
GB2119021.0 2021-12-24
US202217574424A 2022-01-12 2022-01-12
US17/574,424 2022-01-12
EPPCT/EP2022/055324 2022-03-02
EP2022055324 2022-03-02
PCT/EP2022/082486 WO2023089132A1 (fr) 2021-11-18 2022-11-18 Formulations injectables et inhalables

Publications (1)

Publication Number Publication Date
CA3238583A1 true CA3238583A1 (fr) 2023-05-25

Family

ID=84440034

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3238583A Pending CA3238583A1 (fr) 2021-11-18 2022-11-18 Formulations injectables et inhalables

Country Status (11)

Country Link
EP (1) EP4433049A1 (fr)
JP (1) JP2024540527A (fr)
KR (1) KR20240110836A (fr)
AU (1) AU2022393234A1 (fr)
CA (1) CA3238583A1 (fr)
CL (1) CL2024001452A1 (fr)
CO (1) CO2024007518A2 (fr)
IL (1) IL312859A (fr)
MX (1) MX2024005955A (fr)
WO (1) WO2023089132A1 (fr)
ZA (1) ZA202403906B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022553135A1 (en) 2020-05-19 2024-03-04 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666149A1 (fr) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Indoles substitues
US20220071958A1 (en) * 2019-02-22 2022-03-10 GH Research Ireland Limited 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
PT3873883T (pt) 2019-11-07 2023-03-24 Small Pharma Ltd Método de síntese
EP3902541B1 (fr) 2020-06-02 2022-09-14 Small Pharma Ltd Compositions thérapeutiques comprenant des composés de n,n-dimethyltryptamine deutérés ou partiellement deutérés
AU2021334933B2 (en) * 2020-08-28 2023-01-19 Cybin Uk Ltd Injectable formulation
IL303288A (en) * 2020-12-01 2023-07-01 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds

Also Published As

Publication number Publication date
ZA202403906B (en) 2025-08-27
KR20240110836A (ko) 2024-07-16
EP4433049A1 (fr) 2024-09-25
WO2023089132A1 (fr) 2023-05-25
AU2022393234A1 (en) 2024-06-06
CL2024001452A1 (es) 2024-09-27
MX2024005955A (es) 2024-06-11
IL312859A (en) 2024-07-01
JP2024540527A (ja) 2024-10-31
CO2024007518A2 (es) 2024-07-29

Similar Documents

Publication Publication Date Title
US12318477B2 (en) Injectable and inhalable formulations
US11406619B2 (en) Injectable formulations
KR102636385B1 (ko) 주사용 제제
US11660289B2 (en) Deuterated or partially deuterated N,N-dimethyltryptamine compounds
EP4275753A2 (fr) Composés de n,n-diméthyltryptamine deutérés ou partiellement deutérés
US20220062237A1 (en) Injectable formulation
EA002174B1 (ru) Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин
Layzell et al. Injectable formulation
CA3238583A1 (fr) Formulations injectables et inhalables
US20250262145A1 (en) Injectable and inhalable formulations
US20250032450A1 (en) Injectable and inhalable formulations
US20220169606A1 (en) Compositions and compounds for bioanalysis
CN118450893A (zh) 可注射和可吸入的制剂
EA049106B1 (ru) Инъекционная композиция
BR112022022198B1 (pt) Formulação injetável
HK40089095B (en) Injectable formulation
HK40089095A (en) Injectable formulation